GlassScriptPhysician profile
Alex M Arce
NPI 1487061271
$3,649.10
in general payments reported to CMS, 2019-2025
32 companies · $228 in 2025
The $228 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,876 · 2020: $386 · 2021: $29.11 · 2022: $527 · 2023: $342 · 2024: $262 · 2025: $228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $831.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $830.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $873.84 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $406.13 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $392.91 | 2019-2023 | Farxiga, Breztri |
| Glaxosmithkline, LLC. | $334.85 | 2019-2023 | Trelegy Ellipta, Pediarix, Shingrix |
| Kerecis Limited | $274.92 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Surgiclose, Kerecis Omega3 Surgiclose |
| Sanofi-Aventis U.S. LLC | $150.91 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $144.61 | 2019-2022 | |
| Abbvie INC. | $138.06 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.13 | 2019-2023 | Jardiance |
| Organogenesis INC. | $107.15 | 2025 | Affinity |
| Endo Pharmaceuticals INC. | $97.28 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $68.99 | 2019-2020 | |
| Astellas Pharma US INC | $66.47 | 2019-2023 | |
| Dexcom, INC. | $62.42 | 2022 | |
| Abbott Laboratories | $34.93 | 2019-2023 | Freestyle Libre 3 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $34.42 | 2019 | |
| Dynavax Technologies Corporation | $34.29 | 2023 | Heplisav-B |
| Idorsia Pharmaceuticals US INC | $34.05 | 2023 | Quviviq |
| Exact Sciences Corporation | $32.80 | 2023 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $27.65 | 2022-2023 | Eliquis |
| Lilly USA, LLC | $26.21 | 2019 | |
| Xeris Pharmaceuticals, INC. | $23.52 | 2022 | |
| Amarin Pharma, INC. | $23.03 | 2022 | |
| Arbor Pharmaceuticals, INC. | $19.56 | 2019 | |
| Janssen Pharmaceuticals, INC | $18.66 | 2019 | |
| Medtronic Vascular, INC. | $17.49 | 2019 | |
| Daiichi Sankyo INC. | $15.35 | 2019 | |
| Roche Diagnostics Corporation | $15.01 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.00 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $14.72 | 2019 | |
| Corcept Therapeutics | $14.20 | 2021 | |
| Merck Sharp & Dohme LLC | $11.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alex Arce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.